Spanish pharmaceutical company Almirall S.A. (BME:ALM) announced on Monday that it has expanded its strategic collaboration with the Barcelona Supercomputing Center – Centro Nacional de Supercomputación (BSC – CNS) to accelerate innovation in medical dermatology through artificial intelligence and high-performance computing.

The framework agreement builds on prior joint R&D projects and aims to strengthen discovery of new therapies for skin diseases.

As part of the partnership, Almirall joins the 'BSC Connects' programme, which provides access to advanced technologies, tailored support, and training to support co-development of R&D initiatives throughout 2026. The initiative is designed to foster public-private collaboration and will integrate disruptive technologies across Almirall's research and development pipeline.

The collaboration leverages scientific expertise from both organisations to address dermatological research challenges, including areas such as genomics, digital twins, and drug design.

BSC is a key European supercomputing infrastructure hub supporting industry-academia innovation ecosystems.